Videos Archives - Green Market Report

Video StaffVideo StaffSeptember 20, 2018

1min550

The Green Market Summit hosted by the Green Market Report on September 14, 2018, featured a panel that looked into the effect of a legalized adult use marijuana market on existing medical marijuana markets. Panelists included Adam Orens of Marijuana Policy Group, Jeannette Horton and Jessica Billingsley from MJ Freeway and Emily Paxhia of Poseidon Asset Management.

The panel resulted in a new report issued at the Summit titled, “The Economics of Adult Use Marijuana on Medical Marijuana Markets.” The findings from the data provided by MJ Freeway noted that instead of adult use legalization cannibalizing medical marijuana markets, the medical markets turn out to be very resilient.


Video StaffVideo StaffSeptember 19, 2018

1min4860

At last week’s Green Market Summit in New York City, TheStreet’s founder and CNBC star Jim Cramer interviewed The Green Organic Dutchman’s (TGODF) Chief Executive Officer Brian Athaide in a keynote address. Cramer was specifically interested in Athaide’s background at Procter & Gamble (PG) and how that experience would translate to the cannabis industry.

Cramer and Athaide also discussed cannabis company valuations and whether they were too rich. The Constellation Brands (STZ) investment into Canopy Growth Corp. (CGC) was also discussed. Athaide told Cramer that he didn’t think Constellation overpaid at all. He thinks they actually got a good deal. This is a fascinating interview that is well worth watching.

Video editing was performed by Small Cap Nation.


Video StaffVideo StaffSeptember 10, 2018

3min720

Green Table Global recently held an event in Southampton NY bringing together cannabis companies and cannabis investors. It was a beautiful evening and even though it was a Sunday night, there was plenty of interest. Investors listened to presentations from Matt Karnes of GreenWave Advisors, Multiverse Capital, Green Revolution, Franki Global, and Kannalife.

Multiverse Capital is a Venture Capital Firm Investing in all Sectors of the Global Cannabis Industry. The Multiverse name is reflective of our broad-based strategy since it invests in both private and public cannabis companies, globally. Multiverse Capital has 3 distinct cannabis investment venture funds: medicinal, adult use (recreational), and ancillary (real estate, ancillary products & services, and biotech). Multiverse Capital management and advisors have worked with hundreds of private and public cannabis companies in over 15 countries and have a combined 16 years of commercial cannabis and industrial hemp experience.

Green Revolution is the first crossover cannabis health and lifestyle brand in the country. At Green Revolution, the company has created a family of cannabis-based products for all vital dimensions of your life. By using the latest scientific methods and innovative technologies, Green Revolution has become a recognized leader in multiple product categories within the cannabis industry and is poised for national expansion. Its products serve a broad demographic from 21 to 80 and have consistently proven to be the go to option for veteran users as well as people experiencing cannabis for the very first time.

Franki Global Inc. is a unique video-based social media experience via its brand “franki”. franki connects consumers and businesses through an authentic social video review experience. Unlike other review apps, franki invites consumers to create video reviews that share their true opinion and allowing franki users to discover their next adventure – all whilst giving businesses and brands valuable feedback on their products and services.

Kannalife Sciences, based at the Pennsylvania Biotechnology Center is a pharmaceutical and phyto-medical company involved in the research and development of novel therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Kannalife holds an exclusive license with NIH for the commercialization of US Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants” to treat Hepatic Encephalopathy (HE) and an additional license to treat Chronic Traumatic Encephalopathy (CTE).


Video StaffVideo StaffAugust 10, 2018

3min3520

It was a busy week for earnings and most of them came from the biotech side of the industry.

GW Pharmaceuticals reported that its revenue rose 34.6% to $3.5 million and its net loss fell 31.7% to $35.7 million. The company also said it was gearing up for the launch of its drug Epidiolex, which was approved by the FDA by hiring more people. GW also continued to state that it expects cannabis to be rescheduled as a result of the FDA approval.

Insys Therapeutics Inc. (INSY) delivered its second-quarter numbers on Wednesday missing analysts estimates for revenues and earnings. This was following an earlier announcement that it had settled with the Department of Justice saying that it had agreed to pay $150 million over five years.

Arena Pharmaceuticals reported a net loss of $31 million or 65 cents per share, which missed analysts estimates by 3 cents. Don’t worry, the company is sitting on a cash equivalent and investments balance of $592.4 million.

General Cannabis Corp (CANN) announced financial results for the quarter ended June 30, 2018. The company delivered a net loss of $3.6 million for the quarter a 130% drop from the previous year’s loss of $1.5 million for the same time period. The loss per share was ($0.10) versus last year’s loss of ($0.08). Revenues jumped to $1.1 million from last year’s $833,000.

In the non-earnings news – Willam “Beau” Wrigley joined Surterra Wellness’ board and helped the company close a $65 million fundraising round bringing that company’s total raise to $100 million. The medical marijuana company is focused on the Florida and Texas markets.

Navy Capital invested $3 million into Nevada-based Oasis Cannabis. The deal could go higher if the overallotment is taken pushing it to $5.75 million.

Aurora Cannabis entered into an LOI to acquire HotHouse Consulting.

Sugarmade, Inc. (SGMD), a publicly traded cannabis-related hydroponics supply companies is returning to the OTCQB Venture Market.

Mentor Capital, Inc.(MNTR), an M&A and funding provider for the cannabis and medical marijuana sector, will start to trade on the OTCQX Best Market effective today


Video StaffVideo StaffJuly 26, 2018

2min1490

They say the future is female, and there are few places where that is more apparent than in the cannabis industry. Once thought of as a male-dominated industry, women have quickly claimed their place as leaders in this burgeoning industry.

According to Marijuana Business Daily, women make up approximately 27% of C-Suite level positions in the cannabis industry, which doesn’t sound like much until you realize that the national average is only 23%. What is unsettling, is that in 2015 women held 36% of executive control. That is almost a 10% loss of leadership positioning in less than 3 years.

As the market matures and continues to begin attracting more institutional capital, female entrepreneurs will have to work at keeping the industry a level playing field. And collectively, that is what the trends reveal that they are doing.

For women in cannabis, it has become a badge of honor to know that within their new burgeoning industry ready to take the globe by storm, they hold the largest percentage of ownership, management and control of any industry in the world for their gender. Therefore upon recognition of the possibility of losing that title, the women have begun to band together and work toward the goal of making cannabis the first industry in the world to achieve 50% female control.

To read more, download the Axiswire 2018 Trend Report that can be found here.


Video StaffVideo StaffJuly 20, 2018

1min1310

Agricultural technology in the cannabis industry is undergoing some big changes and, in 2018, expect those changes to continue to accelerate towards automated, wireless, and efficient. The biggest catalyst for change is the Canadian cannabis market. Cannabis companies across the nation are signing supply agreements with Canadian provinces, and in order to meet those demands, they are building massive production facilities.

Read more about it in the 2018 Cannabis Trend Report from Axiswire.


Video StaffVideo StaffJuly 20, 2018

3min4302

Tilray priced its $153 million IPO at $17 a share The stock is listed on the NASDAQ exchange and was priced above its estimated $14-$16 price range. The company recently amended the IPO from raising $100 million to $153 million. The stock immediately traded higher to over $23 a share for a gain of 35%.

Aphria Inc. (APHQF) is acquiring Scythian Biosciences Corp. (SCCYF) Latin American and Caribbean assets in a deal valued at $193 million. The acquisition will allow Aphria to quickly expand into Columbia, Argentina, and Jamaica. It will also give Aphria first offer and refusal for Brazil.

Emblem Corp.  (EMMBF) is making a $3 million strategic equity investment into Canadian cannabis company Natura Naturals Inc. In addition to the investment, the two companies have also signed a three-year cannabis supply agreement for Natura to provide Emblem up to 3,000kg of high-quality cannabis flower per year from its Phase 1 cultivation facility. The deal is expected to close later this week.

AmeriCann, Inc. (OTCQB: ACAN), an agricultural-technology company that is developing the next generation state-of-the-art greenhouse cannabis cultivation and processing properties, announced today that it has closed an all-equity financing offering with total proceeds of $3,819,000.

The Green Organic Dutchman paid a dividend in the form of a warrant. The warrant is for a spin-off company that will be called TGOD Acquisitions. TGOD said that it had come across many companies that weren’t a great fit for TGOD, but were good companies none the less.

Green Spirit Industries Inc. (GSRX) has changed its name to GSRX Industries Inc.  The Company will continue trading under ticker symbol “GSRX”.

Aurora Cannabis Inc. (ACBFF) has joined a growing number of cannabis companies working with the Canadian e-commerce platform Shopify. Today, Aurora announced that it had reached an agreement with Shopify to leverage the e-commerce site’s platform to assist in distributing Aurora’s medical and recreational cannabis globally.

 


Video StaffVideo StaffJuly 18, 2018

4min1552

The Green Market Report Cannabis Company Index recovered following a challenging start to the year. After falling 21.9% in the first quarter, the Index on average gained 20% for the second quarter of 2018.

If you’ll recall at the beginning of the year, U.S Attorney General Jeff Sessions rescinded the Cole Memorandum and stocks responded accordingly with many investors taking profits gained in 2017. There was a great deal of fear that the Department of Justice (DOJ) would begin cracking down on the cannabis industry and shareholders wanted no part of that. As it turns out, the DOJ was more bark than bite and very little punitive action has taken place.

The second quarter began a slow climb back up the charts as shareholders began to return to the market comforted by the lack of movement by the DOJ. The quarter was significant for high profile IPO’s like MedMen Enterprises, The Green Organic Dutchman, and Green Thumb Industries. Adding to the excitement, the major stock exchanges in the U.S. opened their doors to Canadian cannabis companies. The NASDAQ welcomed Cronos Group and the New York Stock Exchange-listed Canopy Growth.

Canada’s final legislative approval for legalized adult-use marijuana in June was met with relief and it was capped off by Prime Minister Trudeau’s setting October 17, 2018, as the goal date for sales. Since so many Canadian cannabis companies have built business strategies around this market, it was encouraging to get a green light with a set date. Uncertainty is always unsettling and these final pieces to the legalization puzzle were finally put in place.

The medical market also received the expected good news for GW Pharmaceuticals from the FDA, which approved its cannabinoid drug Epidiolex. This drug will be used to treat rare forms of epilepsy called Dravet Syndrome and Lennox Gastaut. It uses real cannabis plants and is not a synthetic compound. The company had been achieving all of its drug trial study goals and there seemed to be no reason for the FDA to have turned the company down. So, even with positive expectations, getting the final word was heartening.

Still, the FDA made it clear that its approval did not change the scheduling status for cannabis and that the agency would send a recommendation to the DEA, but did not say what that recommendation would be. GW Pharma was more clear and adamantly stated that rescheduling would occur within 90 days.

This approval has many in the cannabis industry feeling that there will be some big moves for the rescheduling question as a result of the FDA’s approval. Even though there really is no guarantee of this happening, most feel that there is no turning back now for cannabis and a change in its classification is inevitable.

You can read the entire  Index Summary here.

 

 



About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 4 hours

$CGC ⁦@CanopyRiversInc⁩ great panel last week at the

@GreenMarketRpt – 4 hours

The good and bad on $TLRY this week.

@GreenMarketRpt – 23 hours

Ready to talk $TLRY ⁦@WallandBroad⁩ on ⁦@cheddar⁩

Back to Top

You have Successfully Subscribed!